OncoMatch/Clinical Trials/NCT06391034
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
Is NCT06391034 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Non-interventional hormone therapy and hyperpolarized pyruvate +/-urea (13C/15N) for prostate cancer.
Treatment: hyperpolarized pyruvate +/-urea (13C/15N) · Non-interventional hormone therapy — This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Excluded: Stage PELVIC REGIONAL OR DISTANT METASTATIC DISEASE
Evidence of pelvic regional or distant metastatic disease on conventional imaging (MRI, computed tomography or whole body bone scan) or prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET) imaging. PSMA-avid lymph nodes confined to the pelvis will be allowed if <1 centimeter (cm).
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
White Blood Cell count (WBC) >=4000 cells/μL; Hemoglobin ≥9.0 gm/dL; Platelets ≥75,000 cells/μL
Kidney function
Renal Function > 30 Epithelial Growth Factor Receptor (eGFR)
Demonstrates adequate organ function as defined below: White Blood Cell count (WBC) >=4000 cells/μL. Hemoglobin ≥9.0 gm/dL. Platelets ≥75,000 cells/μL. Renal Function > 30 Epithelial Growth Factor Receptor (eGFR).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06391034 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages